Market Research Logo

Analyzing Generics Market in China 2017

Analyzing Generics Market in China 2017

China has now become the second biggest pharmaceutical market in the world. The Chinese pharmaceutical industry is expected to reach USD 167 billion by the end of 2020, growing at a CAGR of 9.1%. In 2015, the Chinese pharmaceutical industry had a value of USD 108 billion. Generics is a major segment of the Chinese pharmaceutical industry and the government's policies are geared towards favoring a rapid growth of their generics market. The Chinese generic market is expected to surpass the US in terms of sales by the end of 2017.

The Chinese generics industry has been growing at an extremely strong rate in recent years, even though there is saturation within the overall pharmaceutical market. Generics now account for 90% of the Chinese pharmaceutical industry and the [pattern of rapid growth is expected to continue well past 2020 also.

As the government works towards making generics affordable for the general population, many leading global drug manufacturers are entering the Chinese market as they don't have to absorb the investment costs as compared to the developer of a new drug.

Aruvian Research presents Analyzing Generics Market in China 2017 – a comprehensive coverage of the Chinese generic drugs market. Beginning with a sectional description on the global generic industry, the report looks at an overview of the industry, an analysis of the market volume and value, industry segmentation and an industry forecast.

Moving on, we analyze the Generics Industry in Asia Pacific through the same parameters.

The Generics Industry in China is analyzed through an industry overview which spans the data from 2012 till 2021. An analysis of the industry's value and volume data is included along with an industry segmentation by geography. Industry forecast of the industry is also included.

We also include a Porter’s Five Forces analysis of the Chinese Generics Industry. Generics pricing and reimbursement situation in China and trends and challenges facing the industry are analyzed.

Analysis of the major industry players in the Chinese generics market are analyzed through an analysis of their business segments, a financial analysis and a SWOT analysis. Players analyzed include Cipla Limited, Mylan, Sanofi SA, Teva Pharmaceutical Industries, China Grand Pharmaceutical and Healthcare Holdings and Sandoz International. This concludes this comprehensive research report from Aruvian Research."


A. Executive Summary
B. Analyzing the Global Generics Industry
B.1 Industry Definition
B.2 Industry Overview
B.3 Industry Value & Volume Analysis
B.4 Industry Segmentation by Geography
B.5 Patent Expiries
B.6 Global Generic Industry Structure
B.7 Industry Forecast
C. Generics Industry in Asia Pacific
C.1 Industry Overview
C.2 Industry Value & Volume
C.3 Industry Segmentation by Geography
C.4 Industry Forecast
D. Generics Industry in China
D.1 Industry Overview
D.2 Industry Value & Volume
D.3 Industry Segmentation by Geography
D.4 Industry Forecast
E. Generics Industry in China: Porter’s Five Forces Strategy Analysis
E.1 Introduction
E.2 Bargaining Power of Buyers
E.3 Bargaining Power of Suppliers
E.4 Competitive Rivalry in the Industry
E.5 Threat of New Entrants
E.6 Threat of Substitutes
F. Pricing & Reimbursement in China
F.1 Overview
F.2 Generics Pricing & Reimbursement Scenario
F.3 Trends & Challenges
G. Major Industry Players
G.1 Cipla Limited
G.1.1 Corporate Analysis
G.1.2 Financial Analysis
G.1.3 SWOT Analysis
G.2 Mylan N.V.
G.2.1 Corporate Analysis
G.2.2 Financial Analysis
G.2.3 SWOT Analysis
G.3 Sanofi SA
G.3.1 Corporate Analysis
G.3.2 Financial Analysis
G.3.3 SWOT Analysis
G.4 Teva Pharmaceutical Industries Limited
G.4.1 Corporate Analysis
G.4.2 Financial Analysis
G.4.3 SWOT Analysis
G.5 China Grand Pharmaceutical and Healthcare Holdings Limited
G.6 Sandoz International GmbH
H. Glossary of Terms
List of Figures
Figure 1: Historical Revenues of Leading Generic Companies (in USD Million), 2008-2009
Figure 2: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
Figure 3: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
Figure 4: Global Generics Market Segmentation by Geography (%), 2016
Figure 5: Revenues of Top 10 Drugs that went off Patent between 2010-2014 (in USD Million)
Figure 7: Market Share of Leading Generic Companies Worldwide (%), 2016
Figure 8: Comparison of Revenues of Leading Generic Companies (in USD Million), 2013-2014
Figure 9: Global Generics Industry Forecast (in USD Billion), 2016-2021
Figure 10: Global Generics Industry Forecast by Volume (% of Pharma Volume), 2016-2021
Figure 11: Value of the Asia Pacific Generics Market (in USD Billion), 2012-2016
Figure 12: Volume Growth of the Asia Pacific Generics Market (%), 2012-2016
Figure 13: Share of the Asia Pacific Generics Industry by Countries (%), 2016
Figure 14: Forecast of the Asia Pacific Generics Market (in USD Billion), 2016-2021
Figure 15: Volume Forecast of the Asia Pacific Generics Market (%), 2016-2021
Figure 16: Value of the Generics Market in China (in USD Billion), 2012-2016
Figure 17: Volume Growth of the Generics Market in China (%), 2012-2016
Figure 18: Share of China in the Asia Pacific Generics Industry (%), 2016
Figure 19: Forecast of the Generics Market in China (in USD Billion), 2016-2021
Figure 20: Volume Forecast of the Generics Market in China (%), 2016-2021
Figure 21: Porter's Five Forces Strategy Analysis of the Generics Industry in China
Figure 22: Bargaining Power of Buyers in the Chinese Generics Industry
Figure 23: Bargaining Power of Suppliers in the Chinese Generics Industry
Figure 24: Competitive Rivalry in the Chinese Generics Industry
Figure 25: Threat of New Entrants to the Chinese Generics Industry
Figure 26: Threat of Substitutes to the Chinese Generics Industry
Figure 27: Healthcare Regulatory Agencies in China & their Responsibilities
Figure 28: Revenues & Profitability of Cipla Limited (in USD Million), 2011-2015
Figure 29: Revenues & Profitability of Sanofi SA (in USD Million), 2011-2015
Figure 30: Revenues & Profitability of Teva Pharmaceutical (in USD Million), 2011-2015
Figure 31: Revenues & Profitability of China Grand Pharmaceutical and Healthcare (in USD Million), 2011-2015
List of Tables
Table 1: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
Table 2: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
Table 3: Global Generics Industry, Segmentation by Geography (in USD Billion), 2016
Table 5: Global Generics Industry Forecast (in USD Billion), 2016-2021
Table 6: Global Generics Industry Forecast by Volume & Percentage Growth (% of Pharma Volume), 2016-2021
Table 7: Value of the Asia Pacific Generics Market (in USD Billion), 2012-2016
Table 8: Volume Growth of the Asia Pacific Generics Market (%), 2012-2016
Table 9: Share of the Asia Pacific Generics Industry by Countries (% & USD Billion), 2016
Table 10: Forecast of the Asia Pacific Generics Market (in USD Billion), 2016-2021
Table 11: Volume Forecast of the Asia Pacific Generics Market (%), 2016-2021
Table 12: Value of the Generics Market in China (in USD Billion), 2012-2016
Table 13: Volume Growth of the Generics Market in China (%), 2012-2016
Table 14: Share of China in the Asia Pacific Generics Industry (% & USD Billion), 2016
Table 15: Forecast of the Generics Market in China (in USD Billion), 2016-2021
Table 16: Volume Forecast of the Generics Market in China (%), 2016-2021
Table 17: Key Financials of Cipla Limited (in USD Million), 2011-2015
Table 18: Key Financials of Sanofi SA (in USD Million), 2011-2015
Table 19: Key Financials of Teva Pharmaceutical (in USD Million), 2011-2015
Table 20: Key Financials of China Grand Pharmaceutical and Healthcare (in USD Million), 2011-2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report